|
|
|
© 2023 Octapharma USA, Inc.
All Rights Reserved
Todos los derechos reservados
|
Ivan was diagnosed with severe hemophilia A at two days old, when doctors noticed that his feet were bruised and bleeding. At the time, his parents were not aware of any family history of bleeding disorders. But he did have an uncle who had died at age seven. Looking back, it seems to fit that he died from a bleed associated with a serious injury. Since Ivan's birth, two cousins have also been diagnosed with severe hemophilia. But hemophilia is not the only thing that runs in his family. “Baseball is in my blood. I come from a long line of baseball players – father, grandfather, uncle, brother. So I always played – there was really never any question about it.” Despite his diagnosis, Ivan played baseball throughout his childhood and teen years, even playing semi–pro for two years. Today, in addition to his job as a general contractor, work as an Octapharma Patient Educator, and activities as a busy parent, he coaches teams and runs baseball clinics for youths with bleeding disorders. “I can't get enough.”
Ivan attributes much of his can–do attitude to what he learned from his parents. “I came up in a time when involvement in sports was just not part of the program for kids with hemophilia.” But his parents were different, always encouraging him to play and to pursue what he loved. “Sure, my mom watched games with her eyes closed. And we spent many hours in the ER after sports–related injuries. But nothing could keep me off the field.” Similarly, in his social life, Ivan always felt like just one of the guys. He was very open about his hemophilia, infused in front of his friends, and maintained a large social network and support system. “Some kids, especially teenagers, worry about being different – being made fun of or being bullied. But not me. Yes, I walk with a limp because of damage to my ankle from hemophilia. I always say, ‘That's just how I walk.’” Ivan has carried this positive attitude into adulthood. “Today I tell parents who worry about the safety of their children that ‘kids will be kids’. When they fall, they'll get up. They're going to get cuts and bruises. But they'll also learn how to take care of themselves. They'll become independent. And they'll have fun.”
Like many people with bleeding disorders treated from an early age, Ivan received on–demand infusions at a Hemophilia Treatment Center. “I have had the same nurse my whole life, up until she recently retired. She was a great resource for me and taught me how to self–infuse.” At age 12 he began prophylactic treatment, supplementing with on–demand infusion as needed. And he began treatment at home with self–infusion, with his mom playing shortstop. “My mom ordered all my meds, kept track of my schedule for infusions and appointments, and basically handled everything for me.” When Ivan entered high school, he received a scholarship that took him far from home. Now he had to assume responsibility for managing his treatment. “You can't just run home. I learned to keep track of my factor and my infusion schedule for myself. I always had my contacts at the ready in case I needed help. I was very motivated not to miss a treatment because I always wanted to be back on the baseball diamond.”
Ivan has been on two different factor therapies; on NUWIQ® for the last four years. “On my previous product, I was on an ‘every other day’ regimen. After switching to NUWIQ, I was able to reduce my dosing frequency significantly. So NUWIQ has been perfect for me.” Ivan also did his efficacy research. “If you have hemophilia, you're going to get bleeds. You want the drug that will get you back on your feet fastest. Through my research, I learned that even one on–demand infusion of NUWIQ after an injury could be very effective at resolving a bleed.” His treatment regimen with NUWIQ has been extremely successful. “I don't want to jinx it, but I can't even remember the last time I had a bleed, it's been so long.”
“I have met great people all over the country as a Patient Educator for Octapharma. But I especially love reaching out to the Hispanic community.” Ivan believes that there is a need to get beyond a language barrier, and that resources and support available in Spanish are much appreciated. “That's why I do presentations in Spanish. I want everyone to get the information they need. And to feel connected.”
New to Factor My Way? ¿Es nuevo en Factor My Way? Sign up here. Inscríbase aquí.
You are now leaving an Octapharma property. Links to all outside sites are provided as a resource to our visitors. Octapharma disclaims any and all liability for the content, services, or privacy practices of sites that are not owned and operated by Octapharma. Linking to this site is done at your own risk.
To return to the prior page, close this window or select cancel.
To continue to the offsite link, please select continue.
Está abandonando una propiedad de Octapharma. Los enlaces a todos los sitios externos se proporcionan como un recurso para nuestros visitantes. Octapharma no se hace responsable del contenido, los servicios o las prácticas de privacidad de los sitios que no son propiedad de Octapharma ni son operados por Octapharma. Usted visita este sitio por su propia cuenta y riesgo.
Para volver a la página anterior, cierre esta ventana o seleccione Cancelar.
Para continuar al enlace fuera del sitio, seleccione Continuar
Those with Medicare, Medicaid, Medigap, VA, DOD, Tricare or other federal or state government insurance are not eligible to receive co-pay assistance.
Quienes tengan Medicare, Medicaid, Medigap, VA, DOD, Tricare u otro seguro del gobierno federal o estatal no son elegibles para recibir ayuda con los copagos.
We will email you once this event has been scheduled so that you can sign up. Le enviaremos un correo electrónico una vez que este evento haya sido programado para que pueda inscribirse.
Event: Evento:
Date: Fecha:
Presenter: Presentador:
Check your email for event confirmation and participation details from Zoom. You should receive the email within about five minutes. The email will be sent to you by no-reply@zoom.us. If you do not see the confirmation email in your inbox, please check your Spam folder, and if the email is there, mark it as "not spam" and add no-reply@zoom.us to your Address Book. If you can’t locate the email at all, please reach out to your Factor My Way Patient Experience Manager. Revise su correo electrónico para ver la confirmación del evento y los detalles sobre la participación de Zoom. Debería recibir el correo electrónico dentro de aproximadamente cinco minutos. El correo electrónico se enviará desde no-reply@zoom.us. Si no ve el correo electrónico de confirmación en la bandeja de entrada, consulte la carpeta de correo no deseado y, si el correo está allí, máquelo como “no es correo no deseado” y agregue no-reply@zoom.us a su libreta de direcciones. Si no puede encontrar el correo electrónico, comuníquese con el director de Experiencia del Paciente de Factor My Way.
Already a member? ¿Ya es miembro? Sign-in here Inicie sesión aquí
Thank you for your submission.
Your local Patient Experience Manager will contact you within two to three business days to facilitate your meeting request with Patient Educator .
Gracias por su envío.
Su director de Experiencia del Paciente se comunicará con usted dentro de dos o tres días hábiles para facilitar su solicitud para reunirse con el paciente educador .
This material represents individual patient and/or caregiver experience living with a bleeding disorder.
This content is not intended to be a substitute for professional medical advice, diagnosis or treatment. Please consult with your local Hemophilia Treatment Center physician or other health care provider if you have any questions related to management of bleeding disorders.
Este material representa la experiencia individual de un paciente o cuidador que vive con un trastorno hemorrágico
Este contenido no tiene como objetivo reemplazar el consejo, diagnóstico o tratamiento médico profesional. Consulte con el médico de su Centro de Tratamiento para la Hemofilia local u otro proveedor de atención médica si tiene preguntas relacionadas con el manejo de los trastornos hemorrágicos.
This website uses cookies and stores information on your computer. Some of them are essential to improve our website and your user experience. By using this website, you agree to the use of these cookies. Please check our Data Privacy Statement for more details.
Este sitio web utiliza cookies y almacena información en su computadora. Algunas de ellas son fundamentales para mejorar nuestro sitio web y su experiencia de usuario. Al utilizar este sitio web, acepta el uso de estas cookies. Consulte nuestra Declaración de privacidad de datos para obtener más detalles. Declaración de privacidad de datos para obtener más detalles.
Indications and Important Safety Information for NUWIQ® [Antihemophilic Factor (Recombinant)].
Please see NUWIQ full Prescribing Information. Instructions For Use
Indications and Usage
NUWIQ® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ® is not indicated for the treatment of von Willebrand Disease.
Contraindications
NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.
Warnings and Precautions
Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.
The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).
Adverse Reactions
The most frequently occurring adverse reactions (>5%) in clinical trials were upper respiratory tract infection, headache, fever, cough, lower respiratory tract infection, rhinitis, chills, abdominal pain, arthralgia, anemia, and pharyngitis.
Please see NUWIQ full Prescribing Information. Instructions For Use
Indicaciones e Información de seguridad importante de NUWIQ® [factor antihemofílico (recombinante)].
Consulte la Información de prescripción completa de NUWIQ. Instrucciones de uso
Indicaciones y uso
NUWIQ® es un factor antihemofílico recombinante [factor VIII para la coagulación (factor VIII)] indicado en adultos y niños con hemofilia A para el tratamiento y el control a demanda de los episodios hemorrágicos, el control perioperativo de las hemorragias y profilaxis de rutina con el fin de reducir la frecuencia de los episodios hemorrágicos. NUWIQ® no está indicado para el tratamiento de la enfermedad de von Willebrand.
Contraindicaciones
NUWIQ está contraindicado en pacientes que hayan manifestado reacciones de hipersensibilidad al producto o sus componentes, como anafilaxia, que ponen en riesgo la vida.
Advertencias y precauciones
Es posible que NUWIQ cause reacciones de hipersensibilidad, como anafilaxia. Los primeros signos de reacciones de hipersensibilidad que pueden progresar y derivar en anafilaxia incluyen angioedema, opresión en el pecho, disnea, sibilancias, urticaria o prurito. Si se producen reacciones de hipersensibilidad, suspenda la administración de inmediato e inicie el tratamiento adecuado.
Se pueden formar anticuerpos neutralizantes (inhibidores) del factor VIII luego de administrar NUWIQ. Controle a todos los pacientes para detectar el desarrollo de inhibidores del factor VIII mediante observaciones clínicas y análisis de laboratorio adecuados. Si el nivel del factor VIII en plasma no aumenta según lo esperado o si la hemorragia no se controla luego de la administración de NUWIQ, se debe sospechar la presencia de un inhibidor (anticuerpo neutralizante).
Reacciones adversas
Las reacciones adversas más frecuentes (>5%) que tuvieron lugar en ensayos clínicos fueron infección del tracto respiratorio superior, dolor de cabeza, fiebre, tos, infección del tracto respiratorio inferior, rinitis, escalofríos, dolor abdominal, artralgia, anemia, y faringitis.
Consulte la Información de prescripción completa de NUWIQ. Instrucciones de uso
Indications and Important Safety Information for wilate® [von Willebrand Factor/Coagulation Factor VIII Complex (Human)].
Please see wilate full Prescribing Information.
Indications
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in children and adults with von Willebrand disease for on-demand treatment and control of bleeding episodes and for perioperative management of bleeding. wilate is also indicated in adolescents and adults with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes; and for on-demand treatment and control of bleeding episodes.
Contraindications
wilate® is contraindicated in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reactions, to human plasma-derived products, any ingredient in the formulation, or components of the container.
Warnings and Precautions
Hypersensitivity Reactions
Hypersensitivity reactions may occur with wilate®. Signs and symptoms include angioedema, burning and stinging at the infusion site, chills, flushing, generalized urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, and wheezing that may progress to severe anaphylaxis (including shock) with or without fever. Closely monitor patients receiving wilate® and observe for any symptoms throughout the infusion period.
Because inhibitor antibodies may occur concomitantly with anaphylactic reactions, evaluate patients experiencing an anaphylactic reaction for the presence of inhibitors
Thromboembolic Events
In VWD, continued treatment using a FVIII-containing VWF product may cause an excessive rise in FVIII activity, which may increase the risk of thromboembolic events. Monitor plasma levels of VWF:RCo and FVIII activities in patients receiving wilate to avoid sustained excessive VWF and FVIII activity levels.
Neutralizing Antibodies
VWD
Hemophilia A
Transmissible Infectious Agents
wilate® is made from human plasma. Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent. There is also the possibility that unknown infectious agents may be present in the product. The risk that wilate® will transmit viruses has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and removing certain viruses during manufacture. Despite these measures, it may still potentially transmit disease.
Record the batch number of the product every time wilate® is administered to a patient, and consider appropriate vaccination (against hepatitis A and B virus) of patients in regular/repeated receipt of wilate®. ALL infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Octapharma USA, Inc., at 1-866-766-4860.
Monitoring and Laboratory Tests
Adverse Reactions
The most common adverse reactions to treatment with wilate (≥ 1%) in patients with VWD were hypersensitivity reactions, urticaria, and dizziness. The most common adverse reactions to treatment with wilate (≥ 1%) in previously treated patients with hemophilia A was pyrexia (fever).
Please see wilate full Prescribing Information.
Indicaciones e Información de seguridad importante de wilate® [complejo de factor de von Willebrand/factor VIII de la coagulación (humanos)].
Consulte la Información de prescripción completa de wilate.
Indicaciones
wilate® es un complejo de factor de von Willebrand/factor VIII de la coagulación (humanos) indicado en niños y adultos con enfermedad de von Willebrand para el tratamiento y el control a demanda de los episodios hemorrágicos y para el control perioperativo de las hemorragias. wilate también se indica en adolescentes y adultos con hemofilia A para profilaxis de rutina con el fin de reducir la frecuencia de los episodios hemorrágicos; y para el tratamiento y el control a demanda de los episodios hemorrágicos.
Contraindicaciones
wilate® está contraindicado en pacientes con reacciones de hipersensibilidad conocidas, incluidas las reacciones anafilácticas o las reacciones sistémicas graves a productos derivados de plasma humano, cualquier ingrediente de la formulación o los componentes del envase.
Advertencias y precauciones
Reacciones de hipersensibilidad
Pueden producirse reacciones de hipersensibilidad con el uso de wilate®. Los signos y síntomas incluyen angioedema, ardor y picazón en el lugar de la infusión, escalofríos, sofoco, urticaria generalizada, dolor de cabeza, ronchas, hipotensión, letargo, náuseas, inquietud, taquicardia, opresión en el pecho, hormigueo, vómitos y sibilancias que pueden progresar y derivar en anafilaxia grave (incluido shock) con o sin fiebre. Controle de cerca a los pacientes que reciban wilate® y preste atención a cualquier síntoma durante el período de infusión.
Debido a que los anticuerpos inhibidores pueden desarrollarse de forma concomitante con las reacciones anafilácticas, evalúe a los pacientes que experimenten una reacción anafiláctica para detectar la presencia de inhibidores.
Anticuerpos neutralizantes
Enfermedad de von Willebrand
Hemofilia A
Agentes infecciosos transmisibles
wilate® está hecho a partir de plasma humano. Debido a que este producto está hecho de sangre humana, puede implicar un riesgo de transmisión de agentes infecciosos, como virus y, en teoría, el agente de la variante de la enfermedad de Creutzfeldt-Jakob (vCJD). También existe la posibilidad de que haya agentes infecciosos desconocidos en el producto. El riesgo de que wilate® transmita virus se ha reducido mediante la realización de pruebas de detección a los donantes de plasma para detectar la exposición previa a determinados virus, mediante análisis para detectar la presencia de ciertas infecciones virales actuales y mediante la desactivación y eliminación de determinados virus durante la fabricación. A pesar de estas medidas, aún existe la posibilidad de que transmita enfermedades.
Registre el número de lote del producto cada vez que wilate® se administre a un paciente y considere aplicar las vacunas adecuadas (contra los virus de la hepatitis A y B) a los pacientes que reciban wilate® de manera regular o repetida. TODAS las infecciones que un médico considere que se pueden haber transmitido a través de este producto deben ser informadas por el médico u otro proveedor de atención médica a Octapharma USA, Inc., al 1-866-766-4860.
Control y análisis de laboratorio
Reacciones adversas
Las reacciones adversas más comunes al tratamiento con wilate (≥ 1 %) en pacientes con enfermedad de von Willebrand fueron reacciones de hipersensibilidad, urticaria y mareos. La reacción adversa más común al tratamiento con wilate (≥ 1 %) en pacientes con hemofilia A previamente tratados fue pirexia (fiebre).
Consulte la Información de prescripción completa de wilate.
|
|
|
|
© 2023 Octapharma USA, Inc.
All Rights Reserved
Todos los derechos reservados
|